LakeShore Biopharma Co Ltd
LSB0.720USD
-0.010-1.37%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
13.74MValor de mercado
--P/L TTM
Mais detalhes de LakeShore Biopharma Co Ltd Empresa
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Informações da empresa
Código da empresaLSB
Nome da EmpresaLakeShore Biopharma Co Ltd
Data de listagemJul 30, 2021
CEOMr. Dave Chenn
Número de funcionários758
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 30
Endereço- -
Cidade- -
Bolsa de valoresNASDAQ Capital Market Consolidated
País- -
Código postal- -
Telefone- -
Site- -
Código da empresaLSB
Data de listagemJul 30, 2021
CEOMr. Dave Chenn
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
Investidores
Investidores
Proporção
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
Tipos de investidores
Investidores
Proporção
Corporation
65.09%
Individual Investor
13.80%
Research Firm
2.54%
Investment Advisor
0.35%
Private Equity
0.34%
Investment Advisor/Hedge Fund
0.26%
Hedge Fund
0.03%
Other
17.60%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
28
16.97M
69.54%
+11.17M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
2023Q1
71
6.78M
73.08%
+4.90M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Apex Prospect Ltd
9.84M
51.55%
+9.84M
--
Feb 08, 2024
Zhang (Yi)
4.91M
25.73%
--
--
Feb 16, 2024
TD Securities, Inc.
1.05M
5.49%
+1.05M
--
Mar 31, 2025
Shao (Hui)
313.64K
1.64%
+108.76K
+53.09%
Jun 30, 2024
OrbiMed Advisors, LLC
140.43K
0.74%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
116.51K
0.61%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
75.18K
0.39%
--
--
Mar 31, 2025
Superstring Capital Management LP
30.79K
0.16%
--
--
Mar 31, 2025
Barclays Bank PLC
24.76K
0.13%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Data
Tipo
Proporção
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
